Transcutaneous immunotherapy of pollinosis using solid-in-oil nanodispersions loaded with T cell epitope peptides

Kong, Qingliang; Kitaoka, Momoko; Wakabayashi, Rie; Kamiya, Noriho; Goto, Masahiro

doi:10.1016/j.ijpharm.2017.07.020

Cited by 10 publications

(18 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The S/O nanodispersions were prepared according to a previously described method (Figure S1) [27]. Briefly, an aqueous solution of antigen (PE or PE-GM, 0.5 mg/mL, 2 mL) and a cyclohexane solution of sucrose laurate L-195 (12.5 mg/mL, 4 mL) were homogenized with a polytron homogenizer (Kinematica AG, Luzern, Switzerland) at 26,000 rpm for 2 min to form a water-in-oil (W/O) emulsion.…”

Section: Methodsmentioning

confidence: 99%

“…S/O nanodispersions are composed of nanosized particles of a hydrophilic antigen coated by a hydrophobic surfactant molecule dispersed into an oil vehicle [22,23]. In previous studies, peptides, as well as proteins, were encapsulated into S/O nanodispersions and penetrated the hydrophobic SC assisted by surfactants and an oil vehicle [24,25,26,27]. Although our previous studies reported the TCIT of pollinosis using T cell epitope peptides [8,27], no study has focused on the transcutaneous delivery of modified antigen PE-GM for TCIT of pollinosis.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Transcutaneous Delivery of Immunomodulating Pollen Extract-Galactomannan Conjugate by Solid-in-Oil Nanodispersions for Pollinosis Immunotherapy

et al. 2019

Self Cite

View full text Add to dashboard Cite

Japanese cedar pollinosis is a type I allergic disease and has already become a major public health problem in Japan. Conventional subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) cannot meet patients’ needs owing to the side effects caused by both the use of conventional whole antigen molecules in the pollen extract and the administration routes. To address these issues, a surface-modified antigen and transcutaneous administration route are introduced in this research. First, the pollen extract (PE) was conjugated to galactomannan (PE-GM) to mask immunoglobulin E (IgE)-binding epitopes in the PE to avoid side effects. Second, as a safer alternative to SCIT and SLIT, transcutaneous immunotherapy (TCIT) with a solid-in-oil (S/O) nanodispersion system carrying PE-GM was proposed. Hydrophilic PE-GM was efficiently delivered through mouse skin using S/O nanodispersions, reducing the antibody secretion and modifying the type 1 T helper (Th1)/ type 2 T helper (Th2) balance in the mouse model, thereby demonstrating the potential to alleviate Japanese cedar pollinosis.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Transcutaneous Delivery of Immunomodulating Pollen Extract-Galactomannan Conjugate by Solid-in-Oil Nanodispersions for Pollinosis Immunotherapy

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…T cell epitope peptide Epitope p246-259 of Cry j 2 Oral Suppression of Th1 and Th2 responses [20,21] Integrated peptide from three epitopes Oral Inhibition of lymph node cell proliferation to epitopes from Cry j 1/2 [22] Rice seed containing peptides from fourteen epitopes Oral - [23] Rice seed containing 7Crp from seven epitopes Oral Inhibition of T-cell proliferative response to Cry j 1 [24] Chicken egg containing 7Crp from seven epitopes Oral Induction of oral tolerance [25] Cry-consensus from five or six epitopes SC Induction of IgG2a, suppression of ratios of IL-4/IFN-γ and IL-5/IFN-γ,Th1 deviation [17,26] 7Crp from seven epitopes SL Induction of IL-10-producing regulatory T cells [27] 7CrpR from seven epitopes T - [28] Mixture of seven epitopes T Suppression of Th1 and Th2 responses [29] [46] 7CrpR from seven epitopes combined with R848 T Induction of IgG 2a/IgE ratio, Th1 deviation [47] ID: intradermal, IM: intramuscular, SC: subcutaneous, SL: sublingual, T: transcutaneous.…”

Section: Allergen Route Mechanism Referencesmentioning

confidence: 99%

“…Kitaoka et al were the first to investigate the use of a S/O nanodispersion carrying the 7Crp antigen in TCIT for JCP [29]. To improve the poor solubility of 7Crp, a triarginine sequence was introduced between the epitopes in 7Crp as a linker; the new hybrid peptide was named 7CrpR.…”

Section: Applications Of S/o Nanodispersions For Tcit Of Jcpmentioning

confidence: 99%

“…To improve the poor solubility of 7Crp, a triarginine sequence was introduced between the epitopes in 7Crp as a linker; the new hybrid peptide was named 7CrpR. The Kitaoka et al were the first to investigate the use of a S/O nanodispersion carrying the 7Crp antigen in TCIT for JCP [29]. To improve the poor solubility of 7Crp, a triarginine sequence was introduced between the epitopes in 7Crp as a linker; the new hybrid peptide was named 7CrpR.…”

Section: Applications Of S/o Nanodispersions For Tcit Of Jcpmentioning

confidence: 99%

See 1 more Smart Citation

Solid-in-Oil Nanodispersions for Transcutaneous Immunotherapy of Japanese Cedar Pollinosis

et al. 2020

Self Cite

View full text Add to dashboard Cite

Japanese cedar pollinosis (JCP) is a common affliction caused by an allergic reaction to cedar pollen and is considered a disease of national importance in Japan. Antigen-specific immunotherapy (AIT) is the only available curative treatment for JCP. However, low compliance and persistence have been reported among patients subcutaneously or sublingually administered AIT comprising a conventional antigen derived from a pollen extract. To address these issues, many research studies have focused on developing a safer, simpler, and more effective AIT for JCP. Here, we review the novel antigens that have been developed for JCP AIT, discuss their different administration routes, and present the effects of anti-allergy treatment. Then, we describe a new form of AIT called transcutaneous immunotherapy (TCIT) and its solid-in-oil (S/O) nanodispersion formulation, which is a promising antigen delivery system. Finally, we discuss the applications of S/O nanodispersions for JCP TCIT. In this context, we predict that TCIT delivery by using a S/O nanodispersion loaded with novel antigens may offer an easier, safer, and more effective treatment option for JCP patients.

show abstract

Formulation‐based approaches for dermal delivery of vaccines and therapeutic nucleic acids: Recent advances and future perspectives

Sallam

Prakash

Kumbhojkar

et al. 2021

Bioengineering & Transla Med

View full text Add to dashboard Cite

A growing variety of biological macromolecules are in development for use as active ingredients in topical therapies and vaccines. Dermal delivery of biomacromolecules offers several advantages compared to other delivery methods, including improved targetability, reduced systemic toxicity and decreased degradation of drugs. However, this route of delivery is hampered by the barrier function of the skin. Recently, a large body of research has been directed towards improving the delivery of macromolecules to the skin, ranging from nucleic acids to antigens, using noninvasive means. In this review, we discuss the latest formulation-based efforts to deliver antigens and nucleic acids for vaccination and treatment of skin diseases. We provide a perspective of their advantages, limitations and potential for clinical translation. The delivery platforms discussed in this review may provide formulation scientists and clinicians with a better vision of the alternatives for dermal delivery of biomacromolecules, which may facilitate the development of new patientfriendly prophylactic and therapeutic medicines.

show abstract

Transcutaneous immunotherapy of pollinosis using solid-in-oil nanodispersions loaded with T cell epitope peptides

Cited by 10 publications

References 24 publications

Transcutaneous Delivery of Immunomodulating Pollen Extract-Galactomannan Conjugate by Solid-in-Oil Nanodispersions for Pollinosis Immunotherapy

Transcutaneous Delivery of Immunomodulating Pollen Extract-Galactomannan Conjugate by Solid-in-Oil Nanodispersions for Pollinosis Immunotherapy

Solid-in-Oil Nanodispersions for Transcutaneous Immunotherapy of Japanese Cedar Pollinosis

Formulation‐based approaches for dermal delivery of vaccines and therapeutic nucleic acids: Recent advances and future perspectives

Contact Info

Product

Resources

About